Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keluoxin Capsule for Diabetic Nephropathy (Parallel, Randomized, Placebo-Controlled)
ChiCTR2100046655Phase 4Recruiting
- Sponsor
- 416 Hospital of Nuclear Industry, the Second Affiliated Hospital of Chengdu Medical College
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) comparing Keluoxin Capsule with Control: Placebo (2 arms). Primary endpoints: mammalian target of rapamycin (mTOR), LC3-II and 1 more. Started Sep 2021; status: recruiting.
02
Drugs
Keluoxin
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100046655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046655.